Current Psychiatry Reports

, Volume 12, Issue 6, pp 563–571

Assessment of Pharmacotherapy for Negative Symptoms of Schizophrenia

  • Elizabeth Hanson
  • Kristin Healey
  • Daniel Wolf
  • Christian Kohler
Article

DOI: 10.1007/s11920-010-0148-0

Cite this article as:
Hanson, E., Healey, K., Wolf, D. et al. Curr Psychiatry Rep (2010) 12: 563. doi:10.1007/s11920-010-0148-0

Abstract

Negative symptoms in schizophrenia include diminished ability to communicate, motivate, and socialize as potentially debilitating aspects of the illness that are associated with long-term impairment. Despite such burden, the domain has been underrepresented in drug development and treatment research. In this article, we review research regarding pharmacotherapy for negative symptoms, with a focus on studies published during the past 2 years. Clearly positive studies were limited to N-methyl-D-aspartate agonists, while antipsychotics and antidepressants did not show substantial benefit, and cognitive enhancers have yielded mixed results. Proof-of-concept studies of other agents such as minocycline and omega fatty acids yielded promising, albeit preliminary findings that warrant replication. Study outcomes and designs are discussed along with implications for future research.

Keywords

SchizophreniaNegative symptomsTreatmentPharmacotherapyNMDA agonist

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Elizabeth Hanson
    • 1
  • Kristin Healey
    • 1
  • Daniel Wolf
    • 1
  • Christian Kohler
    • 1
  1. 1.Schizophrenia Research Center, Department of Psychiatry University of Pennsylvania School of MedicineHospital of the University of PennsylvaniaPhiladelphiaUSA